Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis

Juan A. Pineda*, Karin Neukam, Josep Mallolas, Luis F. López-Cortés, José A. Cartón, Pere Domingo, Santiago Moreno, José A. Iribarren, Bonaventura Clotet, Manuel Crespo, Ignacio de Los Santos, Enrique Ortega, Hernando Knobel, María J. Jiménez-Expósito, Juan Macías

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)


Objective: To assess the frequency of severe liver toxicity in HIV/hepatitis C (HCV)-coinfected patients with advanced liver fibrosis receiving efavirenz (EFV)-based antiretroviral combinations. Methods: One hundred and eighty-nine previously antiretroviral naïve, HIV/HCV-coinfected patients, who started a regimen including two nucleoside analogues plus EFV, and in whom the presence or absence of advanced liver fibrosis could be established, were retrospectively analyzed. Liver fibrosis was evaluated according to a stepwise algorithm including liver biopsy, transient elastography and FIB-4 index. Results: Fifty-six patients had advanced fibrosis - 25 with cirrhosis - and 133 did not. Three (5.4%) subjects with and 9 (6.8%) (p=0.717) without advanced fibrosis developed grade 3-4 transaminase elevation (TE). Grade 4 total bilirubin elevation was seen in 5 (8.9%) patients with advanced fibrosis and in 1 (0.8%) without it (p=0.003). Liver events led to EFV discontinuation in 10 (5.3%) patients, 6 (10.7%) with and 4 (3%) without advanced fibrosis (p=0.031). Conclusions: The hepatic tolerability of EFV was good in HIV/HCV-coinfected patients with advanced liver fibrosis. The frequency of grade 3-4 TE was similar to that observed in patients without advanced fibrosis, there was no death attributable to liver failure caused by drug toxicity and the rate of EFV discontinuations due to liver events was low.

Original languageAmerican English
Pages (from-to)204-211
Number of pages8
JournalJournal of Infection
Issue number2
Publication statusPublished - Feb 2012


  • Cirrhosis
  • Efavirenz
  • Hepatitis C
  • HIV
  • Liver fibrosis
  • Transaminase elevations


Dive into the research topics of 'Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis'. Together they form a unique fingerprint.

Cite this